About this trial
The goal of this study is to examine if Trametinib and Hydroxychloroquine will improve results for patients with advanced pancreatic cancer compared to standard chemotherapy.
Patient Profile
Patients 18 or older with advanced metastatic pancreatic cancer who have previously received at least one line of chemotherapy for metastatic disease, who are not currently suitable for surgery.
Patient’s tumour must be measurable per RECIST 1.1 criteria (Meaning the size of the tumour can be accurately measured on CT scan).
Patient’s tumour must be suitable for biopsy.
ECOG performance status 0 or 1 (This 0-5 scale is used to assess how cancer is affecting a patients daily living ability).
Patients screening blood tests must show normal organ and marrow function as defined by the protocol.
Able to understand and sign a written informed consent document.
Pregnant women and breastfeeding mothers are not eligible.
Women of child-bearing potential or sexually active males must agree to use highly effective contraceptive measures from starting treatment until 16 weeks after the last treatment.
Patient’s cardiac screening (ECG and Echocardiography or MUGA scan) should be with in normal ranges as defined by the protocol.
Patients will not be eligible if they have ongoing toxicity from prior chemotherapy, prior organ transplantation, central nervous system metastases, maculopathy of the eye, retinal vein occlusion (RVO), an active infection or significant disease or medical conditions that, in the opinion of the Doctor, may increase the risk associated with study participation and would make the patient inappropriate for entry into the study.
Where’s this trial being run?
St Vincents University Hospital and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | PaTcH Trial |
|---|---|
| Number: | 20-27 |
| Full Title: | PaTcH Trial: Pilot study to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine |
| Principal Investigator: | Professor Austin Duffy |
|---|---|
| Type: | In-House |
| Sponsor: | Cancer Trials Ireland |
| Recruitment Started: |
Global: N/A Ireland: 09-Feb-2023 |
| Global Recruitment Target: | N/A |
|---|---|
| Ireland Recruitment Target: | 22 |